276 related articles for article (PubMed ID: 17276366)
1. Use of valganciclovir in patients with elevated antibody titers against Human Herpesvirus-6 (HHV-6) and Epstein-Barr Virus (EBV) who were experiencing central nervous system dysfunction including long-standing fatigue.
Kogelnik AM; Loomis K; Hoegh-Petersen M; Rosso F; Hischier C; Montoya JG
J Clin Virol; 2006 Dec; 37 Suppl 1():S33-8. PubMed ID: 17276366
[TBL] [Abstract][Full Text] [Related]
2. Response to valganciclovir in chronic fatigue syndrome patients with human herpesvirus 6 and Epstein-Barr virus IgG antibody titers.
Watt T; Oberfoell S; Balise R; Lunn MR; Kar AK; Merrihew L; Bhangoo MS; Montoya JG
J Med Virol; 2012 Dec; 84(12):1967-74. PubMed ID: 23080504
[TBL] [Abstract][Full Text] [Related]
3. Randomized clinical trial to evaluate the efficacy and safety of valganciclovir in a subset of patients with chronic fatigue syndrome.
Montoya JG; Kogelnik AM; Bhangoo M; Lunn MR; Flamand L; Merrihew LE; Watt T; Kubo JT; Paik J; Desai M
J Med Virol; 2013 Dec; 85(12):2101-9. PubMed ID: 23959519
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous measurement of antibodies to Epstein-Barr virus, human herpesvirus 6, herpes simplex virus types 1 and 2, and 14 enteroviruses in chronic fatigue syndrome: is there evidence of activation of a nonspecific polyclonal immune response?
Manian FA
Clin Infect Dis; 1994 Sep; 19(3):448-53. PubMed ID: 7811864
[TBL] [Abstract][Full Text] [Related]
5. A therapeutic trial of valganciclovir in patients with uveitis and positive Epstein-Barr virus early antigen D IgG titers.
Boonsopon S; Maghsoudlou A; Kombo NE; Foster CS
Eur J Ophthalmol; 2016; 26(1):30-5. PubMed ID: 26350994
[TBL] [Abstract][Full Text] [Related]
6. Serological and virological investigation of the role of the herpesviruses EBV, CMV and HHV-6 in post-infective fatigue syndrome.
Cameron B; Flamand L; Juwana H; Middeldorp J; Naing Z; Rawlinson W; Ablashi D; Lloyd A
J Med Virol; 2010 Oct; 82(10):1684-8. PubMed ID: 20827765
[TBL] [Abstract][Full Text] [Related]
7. Valganciclovir suppressed Epstein Barr virus reactivation during immunosuppression with alemtuzumab.
Gill H; Hwang YY; Chan TS; Pang AW; Leung AY; Tse E; Kwong YL
J Clin Virol; 2014 Apr; 59(4):255-8. PubMed ID: 24507802
[TBL] [Abstract][Full Text] [Related]
8. Ganciclovir is associated with low or undetectable Epstein-Barr virus DNA load in cerebrospinal fluid of patients with HIV-related primary central nervous system lymphoma.
Bossolasco S; Falk KI; Ponzoni M; Ceserani N; Crippa F; Lazzarin A; Linde A; Cinque P
Clin Infect Dis; 2006 Feb; 42(4):e21-5. PubMed ID: 16421782
[TBL] [Abstract][Full Text] [Related]
9. Reactivation of human herpesvirus (HHV) family members other than HHV-6 in drug-induced hypersensitivity syndrome.
Seishima M; Yamanaka S; Fujisawa T; Tohyama M; Hashimoto K
Br J Dermatol; 2006 Aug; 155(2):344-9. PubMed ID: 16882173
[TBL] [Abstract][Full Text] [Related]
10. Antibody responses to Epstein-Barr virus, human herpesvirus 6 and human herpesvirus 7 in patients with chronic fatigue syndrome.
Sairenji T; Yamanishi K; Tachibana Y; Bertoni G; Kurata T
Intervirology; 1995; 38(5):269-73. PubMed ID: 8724857
[TBL] [Abstract][Full Text] [Related]
11. A six-month trial of valacyclovir in the Epstein-Barr virus subset of chronic fatigue syndrome: improvement in left ventricular function.
Lerner AM; Beqaj SH; Deeter RG; Dworkin HJ; Zervos M; Chang CH; Fitzgerald JT; Goldstein J; O'Neill W
Drugs Today (Barc); 2002 Aug; 38(8):549-61. PubMed ID: 12582420
[TBL] [Abstract][Full Text] [Related]
12. Reactivation of herpesvirus type 6 and IgA/IgM-mediated responses to activin-A underpin long COVID, including affective symptoms and chronic fatigue syndrome.
Vojdani A; Almulla AF; Zhou B; Al-Hakeim HK; Maes M
Acta Neuropsychiatr; 2024 Jun; 36(3):172-184. PubMed ID: 38571295
[TBL] [Abstract][Full Text] [Related]
13. Teriflunomide and Epstein-Barr virus in a Spanish multiple sclerosis cohort:
Domínguez-Mozo MI; González-Suárez I; Villar LM; Costa-Frossard L; Villarrubia N; Aladro Y; Pilo B; Montalbán X; Comabella M; Casanova-Peño I; Martínez-Ginés ML; García-Domínguez JM; García-Martínez MÁ; Arroyo R; Álvarez-Lafuente R
Front Immunol; 2023; 14():1248182. PubMed ID: 37841253
[TBL] [Abstract][Full Text] [Related]
14. Impact of valganciclovir on Epstein-Barr Virus polymerase chain reaction in pediatric liver transplantation: preliminary report.
Venturi C; Bueno J; Gavalda J; Tórtola T; Pou L; Medina A; Codina G; Charco R; Pahissa A
Transplant Proc; 2009 Apr; 41(3):1038-40. PubMed ID: 19376420
[TBL] [Abstract][Full Text] [Related]
15. Valacyclovir treatment in Epstein-Barr virus subset chronic fatigue syndrome: thirty-six months follow-up.
Lerner AM; Beqaj SH; Deeter RG; Fitzgerald JT
In Vivo; 2007; 21(5):707-13. PubMed ID: 18019402
[TBL] [Abstract][Full Text] [Related]
16. Immunoreactivation of Epstein-Barr virus due to cytomegalovirus primary infection.
Aalto SM; Linnavuori K; Peltola H; Vuori E; Weissbrich B; Schubert J; Hedman L; Hedman K
J Med Virol; 1998 Nov; 56(3):186-91. PubMed ID: 9783683
[TBL] [Abstract][Full Text] [Related]
17. The differential impact of training stress and final examination stress on herpesvirus latency at the United States Military Academy at West Point.
Glaser R; Friedman SB; Smyth J; Ader R; Bijur P; Brunell P; Cohen N; Krilov LR; Lifrak ST; Stone A; Toffler P
Brain Behav Immun; 1999 Sep; 13(3):240-51. PubMed ID: 10469525
[TBL] [Abstract][Full Text] [Related]
18. Antibodies to Human Herpesviruses in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients.
Blomberg J; Rizwan M; Böhlin-Wiener A; Elfaitouri A; Julin P; Zachrisson O; Rosén A; Gottfries CG
Front Immunol; 2019; 10():1946. PubMed ID: 31475007
[TBL] [Abstract][Full Text] [Related]
19. Unusual presentation of Epstein-Barr virus hepatitis treated successfully with valganciclovir.
Cauldwell K; Williams R
J Med Virol; 2014 Mar; 86(3):484-6. PubMed ID: 24115018
[TBL] [Abstract][Full Text] [Related]
20. Anti-HHV-6 IgG titer significantly predicts subsequent relapse risk in multiple sclerosis.
Simpson S; Taylor B; Dwyer DE; Taylor J; Blizzard L; Ponsonby AL; Pittas F; Dwyer T; van der Mei I
Mult Scler; 2012 Jun; 18(6):799-806. PubMed ID: 22084489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
